

NHS Grampian Formulary Group Decisions for National Cancer Medicines Advisory Group (NCMAG) advice



This document summarises the decisions of the NHS Grampian Formulary Group for [NCMAG](#) advice.

For the latest Formulary Group decisions see the [Grampian Area Formulary website](#).

For the latest NCMAG advice see the [NCMAG advice documents webpage](#).

February 2024

NHS Grampian Formulary Group Decisions for National Cancer Medicines Advisory Group (NCMAG) advice

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
abiraterone acetate 500mg film-coated tablets	102	[Off-label use] In combination with prednisolone and androgen deprivation therapy for the treatment of high-risk hormone-sensitive non-metastatic prostate cancer.	Routinely available in line with national guidance, NCMAG 102 https://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/ncmag_programme/idoc.ashx?docid=5b088b8b-40d0-4473-8ee6-7f5864fb022a&version=1 Updates decision 17/01/23	21/02/2023
abiraterone acetate 500mg film-coated tablets	110	[Off-label use] In combination with prednisolone and androgen deprivation therapy for the treatment of newly diagnosed low-risk metastatic hormone-sensitive prostate cancer patients who are not suitable for currently accessible on-label alternatives.	Routinely available in line with national guidance, NCMAG 110 https://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/ncmag_programme/idoc.ashx?docid=dadb83b0-a558-4933-8578-f49eeb98d4ac&version=1 Updates decision 15/08/23	17/10/2023
carfilzomib 10mg, 30mg, 60mg powder for solution for infusion (Kyprolis®)	104	[Off-label use] Once-weekly regimen in combination with dexamethasone alone for the treatment of adults with multiple myeloma who have received at least one prior therapy.	Routinely available in line with national guidance, NCMAG 104 https://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/ncmag_programme/idoc.ashx?docid=0be71c76-711d-4dba-a057-f9758c25b5a7&version=1	17/01/2023
dabrafenib 50mg, 75mg hard capsules (Tafinlar®) plus trametinib 0.5mg, 2mg film-coated tablets (Mekinist®)	107	[Off-label use] Treatment of patients with locally advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation and with no satisfactory locoregional treatment options.	Routinely available in line with national guidance, NCMAG 107 https://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/ncmag_programme/idoc.ashx?docid=c640228b-6e8c-4471-a905-f686ef1c251d&version=1	16/01/2024
lenalidomide 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg, 25mg hard capsules	103	In combination with dexamethasone for the treatment of adults with previously untreated multiple myeloma who are not eligible for transplant and are suitable for thalidomide-containing regimens.	Routinely available in line with national guidance, NCMAG 103 https://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/ncmag_programme/idoc.ashx?docid=f5da6c93-1233-4c1b-a216-0ed7051c1768&version=1	21/03/2023

NHS Grampian Formulary Group Decisions for National Cancer Medicines Advisory Group (NCMAG) advice

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®)	106	[Off-label use] Treatment of patients with pleural or peritoneal mesothelioma; second or subsequent line.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/11/2023
pazopanib hydrochloride 200mg, 400mg film-coated tablets (Votrient®)	112	[Off-label use] As second line treatment of poor or intermediate risk advanced/metastatic renal cell carcinoma in patients who have received nivolumab in combination with ipilimumab as first line treatment.	Not routinely available as not recommended for use in NHS Scotland, NCMAG 112	20/02/2024
pemetrexed powder for concentrate for solution for infusion	109	[Off-label use] In combination with cisplatin as adjuvant treatment for patients with completely resected stage IIA to IIIA non-squamous, non-small-cell lung cancer.	Routinely available in line with national guidance, NCMAG 109 https://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/ncmag_programme/idoc.ashx?docid=7935c996-ab84-4d7f-b336-46b8aea18616&version=-1 Updates decision 15/08/23	19/09/2023
sunitinib 12.5mg, 25mg, 37.5mg, 50mg capsules	111	As second line treatment of poor or intermediate risk advanced/metastatic renal cell carcinoma in patients who have received nivolumab in combination with ipilimumab as first line treatment.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/02/2024
trastuzumab 150mg, 420mg powder for concentrate for solution for infusion	105	[Off-label use] Reduced treatment duration of 6-months in the neoadjuvant and adjuvant treatment pathways, for adults categorised as lower risk with human epidermal growth factor receptor 2 (HER2) positive early breast cancer (EBC).	Routinely available in line with national guidance, NCMAG 105 https://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/ncmag_programme/idoc.ashx?docid=7bde2905-fff3-4b38-a218-9b6424458726&version=-1	17/01/2023
vinorelbine tartrate 20mg, 30mg, 80mg soft capsule (Navelbine®)	108	[Off-label use] Vinorelbine as a second- or subsequent-line treatment of adult patients with malignant pleural mesothelioma whose disease has progressed on or after platinum-based chemotherapy, with or without prior immunotherapy.	Not routinely available as not recommended for use in NHS Scotland, NCMAG 108 https://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/ncmag_programme/idoc.ashx?docid=07c5a9ae-7389-4a41-8ce7-e1b4f730aa7e&version=-1	16/05/2023